Deep Search
for Better Therapeutics

Molomics advances the search for structurally novel small molecule therapeutics by Artificial Intelligence (AI) through integrating it with Human Collective Intelligence (HCI). As molecules are designed collaboratively in silico between machine and humans, we expect that our drug candidates are more efficacious and safer, increasing the success rates in clinical development.

Therapeutic Focus

  • Our in-house drug discovery programs focus on Parkinson's Disease.
  • We are open for partnering our drug design approach, with Molomics Technology at its heart, in other disease areas.

Molomics Technology

It is very challenging to determine highly effective and safe therapeutics. Molomics Technology overcomes this challenge by integrating Humans Collective Intelligence (HCI) of teams with Artificial Intelligence (AI) to collaboratively design high potential drug candidates with diverse structures in real-time. The process generates quality drug information by machine learning methods and human knowledge to come up with optimal drug candidates.

Advantages

Artificial Intelligence
(e.g. Machine Learning)

Human Intelligence

Consensus Decision Making

Drug Discovery

Molomics focuses on Parkinson's Disease (PD). Our current programs address Levadopa Induced Dyskinesia (LID). PD_LID_1 works on a partially clinically validated target. PD_LID_2 focuses on a dual drug, binding two targets with synergistic effects.

Our drug discovery programs advance through three phases: the Feasibility Study, the Drug Design Phase and a partial Preclinical Analysis. The green coloured area shows the current stage of our PD_LID_1 program.

Optimizing Your Drug Candidates

Molomics wants to partner with selected biotechs or pharma companies in their disease area of interest. Molomics drug design approach, driven by its proprietary technology, is further re-inforced by state of the art project management:

We can address Multiple Biological Targets but also Phenotypic Screens

We determine a Success Probability of each project

Projects are based on Milestones

Track Project Advances in real-time through Molomics Technology

Include your Specialists with their Capabilities, Knowledge and Logic

Interested in Our Parkinson Products?

We are open to partner our in-house Parkinson drug discovery programs in their advanced development stages.
Please feel free to contact us

Team

Jascha Blobel, PhD
Chief Executive Officer
Giovanni Cincilla, PhD
Chief Scientific Officer
Simone Masoni
Chief Technology Officer

Advisory Board

Nathan Brown, PhD
Scientific Advisor
Head of Cheminformatics; BenevolentAI
Friedhelm Blobel, PhD
Business Advisor
CEO; BioBloC

Supported by

Media / Events

October 29
Molomics chairs the "Artificial Intelligence in Drug Discovery" track at the 2nd Medicinal Chemistry Summit Europe in London
September 25
Molomics attends BioSpain 2018 in Sevilla
September 16
Molomics attends EuroQSAR 2018 in Thessaloniki
June 20
Molomics is selected to pitch at the Fòrum d'Inversió d'Acció in Barcelona
June 11
Molomics attends JavaBCN Conf 2018 in Barcelona
May 14
Molomics advisor attends BioEquity 2018 in Ghent
March 6
Molomics attends KNIME Spring Summit 2018 in Berlin
December 21
Successful Feasibility Study determines structurally new molecules
November 20
Molomics presents at the 20° Foro de Inversión Healthcare in Barcelona
November 5
Molomics attends BioEurope 2017 in Berlin
July 17
Molomics moves to the Parc Científic de Barcelona
June 19
Molomics attends JavaBCN Conf 2017 in Barcelona
March 20
Molomics attends BioEurope Spring 2017 in Barcelona
February 9
first loan received
January 30
publication of Lead Designer
October 20
Molomics presents at Drug Discovery Innovation Programme in Hamburg
June 29
Molomics attends Gamelab 2016 in Barcelona
June 6
Molomics attends BIO 2016 in San Francisco
January 13
first grant received
August 7
first patent filed
August 5
Nathan Brown becomes scientific advisor
June 24
Molomics attends Gamelab 2015 in Barcelona
June 15
Molomics attends BIO 2015 in Philadelphia
April 10
collaboration with Wuji House starts
March 24
first game played by alpha tester
February 27
San Francisco angel joins us
January 9
Molomics is established in Barcelona
Molomics
Parc Científic de Barcelona
Baldiri i Reixac 4-8
08028 Barcelona, Spain